CNS Pharmaceuticals, Inc.
Biotech developing drugs that cross the blood-brain barrier for brain and CNS cancers.
CNSP | US
Overview
Corporate Details
- ISIN(s):
- US18978H1023
- LEI:
- Country:
- United States of America
- Address:
- 2100 WEST LOOP SOUTH, 77027 HOUSTON
- Website:
- https://cnspharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's primary therapeutic focus is on glioblastoma multiforme (GBM), an aggressive and often incurable form of brain cancer. Its development pipeline features anti-cancer drug candidates, including its lead drug Berubicin, which are designed to cross the blood-brain barrier to effectively target brain malignancies. CNS Pharmaceuticals aims to advance transformative therapies through pioneering research to improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CNS Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CNS Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CNS Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Swedencare_AB_publ-logo.png){kind=logo}
